Rigel Pharmaceuticals | RIGL - Debt


Rigel Pharmaceuticals reported $59.69M in Debt for its fiscal quarter ending in June of 2024.





Debt Change Date
Agenus USD 35.54M 2.34M Mar/2025
Amgen USD 57.3B 19M Jun/2026
Anika Therapeutics USD 0 0 Mar/2025
Arrowhead Research USD 983.69M 5.77M Jun/2026
AstraZeneca USD 32.24B 1.68B Jun/2026
BioMarin Pharmaceutical USD 4.19B 11.99M Sep/2026
Bristol-Myers Squibb USD 42.88B 2.18B Sep/2026
Celldex Therapeutics USD 4.9M 3M Jun/2026
Daiichi Sankyo JPY 500.48B 200B Jun/2026
Eli Lilly USD 54.91B 11.54B Jun/2026
Halozyme Therapeutics USD 2.15B 2.02M Jun/2026
Heron Therapeutics USD 149.65M 157K Sep/2024
Intrexon USD 0 13.82M Jun/2024
Ionis Pharmaceuticals USD 1.77B 141M Sep/2026
Karyopharm Therapeutics USD 299.23M 35.14M Dec/2025
Ligand Pharmaceuticals USD 1.13B 679.48M Jun/2026
MacroGenics USD 35.09M 1.42M Jun/2026
Neurocrine Biosciences USD 392.3M 9.5M Sep/2026
Pfizer USD 62.67B 523M Sep/2026
Regeneron Pharmaceuticals USD 2.71B 400K Jun/2026
Rigel Pharmaceuticals USD 59.69M 90K Jun/2024
Sangamo BioSciences USD 0 0 Jun/2022
Ultragenyx Pharmaceutical USD 36M 2.17M Dec/2025
Veracyte USD 40.11M 774K Jun/2026